Avadel Pharmaceuticals PLC at Stifel CNS Days (Virtual) Transcript
Great. Thanks very much and good afternoon, everybody. Appreciate you continuing on to listen in here. It's my pleasure to be moderating the panel with Greg Divis, CEO of Avadel. Greg, it's always fun. Maybe you could kick things off with some opening remarks and just say what you can say about the ongoing FT218 review and your launch prep, and then we can get into specifics. So thanks again.
Yeah. First of all, Paul, thanks. We always appreciate the opportunity to participate in these chats with you and talk to some of your clients. So maybe I'll just frame things up a little bit and provide a little bit of background as well to set the stage. Just as a reminder for folks, we originally had a target PDUFA date of October 15. We were notified that just at that time that the FDA needed more time to complete the review, but they didn't have any questions for us at that point in time.
Clearly, the review progressed through the balance of last year and more work
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |